The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.

Verrica Pharmaceuticals Inc. submitted a New Drug Application to the U.S. Food and Drug Administration for VP-102 (cantharidin 0.7% topical solution) for the treatment of molluscum contagiosum.

U.S. FDA staff reviewers said Paratek Pharmaceuticals Inc.’s potential new antibiotic is not inferior to current treatments.